STOCK TITAN

[Form 4] Owlet, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Owlet (OWLT): Director and 10% owner reports warrant-for-share exchange. On 10/10/2025, Eclipse Early Growth Fund I, L.P. exchanged previously issued Series A and Series B warrants for 3,898,906 shares of Common Stock, at approximate ratios of 0.61 and 0.56 shares per warrant, respectively. The transaction was reported as exempt under Rule 16b-3.

Following the exchange, indirect beneficial ownership reported includes 5,665,669 shares via Eclipse EGF I, 968,694 shares via Eclipse Ventures Fund I, and 1,066,472 shares via Eclipse Continuity Fund I. The Series A (5,300,291 underlying shares) and Series B (1,166,935 underlying shares) warrant positions were reduced to 0.

Owlet (OWLT): Direttore e proprietario del 10% segnala uno scambio warrant-per-condivisione. Il 10/10/2025, Eclipse Early Growth Fund I, L.P. ha scambiato warrant emessi in precedenza Series A e Series B per 3.898.906 azioni ordinarie, a rapporti approssimativi di 0,61 e 0,56 azioni per warrant, rispettivamente. La transazione è stata riportata come esente ai sensi della Rule 16b-3.

Dopo lo scambio, la proprietà indiretta beneficiaria riportata comprende 5.665.669 azioni tramite Eclipse EGF I, 968.694 azioni tramite Eclipse Ventures Fund I, e 1.066.472 azioni tramite Eclipse Continuity Fund I. Le posizioni warrant Series A (5.300.291 azioni sottostanti) e Series B (1.166.935 azioni sottostanti) sono state ridotte a 0.

Owlet (OWLT): Director y propietario del 10% reporta un intercambio warrant-por-acciones. El 10/10/2025, Eclipse Early Growth Fund I, L.P. intercambió warrants emitidos previamente de la Serie A y la Serie B por 3,898,906 acciones ordinarias, a ratios aproximados de 0,61 y 0,56 acciones por warrant, respectivamente. La transacción se reportó como exenta bajo la Regla 16b-3.

Tras el intercambio, la propiedad beneficiaria indirecta reportada incluye 5.665.669 acciones vía Eclipse EGF I, 968.694 acciones vía Eclipse Ventures Fund I, y 1.066.472 acciones vía Eclipse Continuity Fund I. Las posiciones de warrantes de la Serie A (5.300.291 acciones subyacentes) y Serie B (1.166.935 acciones subyacentes) se redujeron a 0.

Owlet (OWLT): 이사 겸 10% 소유주가 워런트-주식 교환을 보고합니다. 2025년 10월 10일, Eclipse Early Growth Fund I, L.P.는 미발행 시리즈 A 및 시리즈 B 워런트를 3,898,906주의 보통주로 교환했으며, 각각 대략 0.610.56 워런트당 주식비율에 해당합니다. 이 거래는 Rule 16b-3에 따라 면책으로 보고되었습니다.

교환 후 간접적 유익 소유는 Eclipse EGF I를 통해 5,665,669주, Eclipse Ventures Fund I를 통해 968,694주, Eclipse Continuity Fund I를 통해 1,066,472주를 포함합니다. 시리즈 A의 기초주 5,300,291주와 시리즈 B의 기초주 1,166,935주는 각각 0으로 감소했습니다.

Owlet (OWLT) : Le directeur et propriétaire de 10% déclare un échange warrant-contre-action. Le 10/10/2025, Eclipse Early Growth Fund I, L.P. a échangé des warrants émis antérieurement des séries A et B contre 3 898 906 actions ordinaires, à des ratios approximatifs de 0,61 et 0,56 actions par warrant, respectivement. La transaction a été déclarée exemptée en vertu de la Rule 16b-3.

Suite à l'échange, la propriété bénéficiaire indirecte reportée comprend 5 665 669 actions via Eclipse EGF I, 968 694 actions via Eclipse Ventures Fund I et 1 066 472 actions via Eclipse Continuity Fund I. Les positions warrants de la série A (5 300 291 actions sous-jacentes) et de la série B (1 166 935 actions sous-jacentes) ont été ramenées à 0.

Owlet (OWLT): Direktor und 10%-Eigentümer meldet warrant-zu-aktie Tausch. Am 10.10.2025 tauschte Eclipse Early Growth Fund I, L.P. zuvor ausgegebene Serien-A- und Serien-B-Warrants gegen 3.898.906 Stammaktien zu ungefährem Verhältnis von 0,61 bzw. 0,56 Aktien pro Warrants, bzw. Die Transaktion wurde gemäß Rule 16b-3 als befreit berichtet.

Nach dem Austausch umfasst die indirekte begünstigte Eigentümerschaft 5.665.669 Aktien über Eclipse EGF I, 968.694 Aktien über Eclipse Ventures Fund I und 1.066.472 Aktien über Eclipse Continuity Fund I. Die Warrants-Positionen der Serie A (5.300.291 zugrundeliegende Aktien) und Serie B (1.166.935 zugrundeliegende Aktien) wurden auf 0 reduziert.

أوليت (OWLT): المدير ومالك 10% يعلن عن تبادل warrants مقابل أسهم. في 10/10/2025، قامت Eclipse Early Growth Fund I, L.P. بتبادل warrants منSeries A وSeries B الصادرة سابقاً مقابل 3,898,906 أسهم عادية، بمقادير تقريبية من 0,61 و0,56 أسهم لكل warrant، على التوالي. تم الإبلاغ عن الصفقة كمعفاة بموجب القاعدة 16b-3.

بعد التبادل، يشمل الملكية المفيدة غير المباشرة المُبلغ عنها 5,665,669 سهمًا عبر Eclipse EGF I، و968,694 سهمًا عبر Eclipse Ventures Fund I، و1,066,472 سهمًا عبر Eclipse Continuity Fund I. تم تقليل وضع Warrants الفئة A (5,300,291 سهمًا أساسياً) والفئة B (1,166,935 سهمًا أساسياً) إلى 0.

Owlet (OWLT): 董事兼10%所有者报告权证对股权的交换。 2025年10月10日,Eclipse Early Growth Fund I, L.P. 将先前发行的A系列和B系列权证兑换为3,898,906股普通股,大致比例为0.610.56股/权证,分别为。该交易被按Rule 16b-3豁免披露。

交换后,间接有效所有权报告包括通过Eclipse EGF I的5,665,669股、通过Eclipse Ventures Fund I的968,694股,以及通过Eclipse Continuity Fund I的1,066,472股。Series A(5,300,291股基础股)和Series B(1,166,935股基础股)的权证头寸降至0

Positive
  • None.
Negative
  • None.

Insights

Warrants canceled in exchange for 3.9M shares; neutral impact.

Eclipse EGF I swapped Series A and B warrants for 3,898,906 common shares. This replaces derivative exposure with outright equity, simplifying the holder’s position. The filing cites a Rule 16b-3 exemption.

Post-transaction, the holder reports indirect stakes of 5,665,669, 968,694, and 1,066,472 shares across affiliated funds. Warrant balances tied to 5,300,291 and 1,166,935 underlying shares are now 0.

Actual market impact depends on future trading decisions by the reporting entities and any resale arrangements permitted under applicable rules.

Owlet (OWLT): Direttore e proprietario del 10% segnala uno scambio warrant-per-condivisione. Il 10/10/2025, Eclipse Early Growth Fund I, L.P. ha scambiato warrant emessi in precedenza Series A e Series B per 3.898.906 azioni ordinarie, a rapporti approssimativi di 0,61 e 0,56 azioni per warrant, rispettivamente. La transazione è stata riportata come esente ai sensi della Rule 16b-3.

Dopo lo scambio, la proprietà indiretta beneficiaria riportata comprende 5.665.669 azioni tramite Eclipse EGF I, 968.694 azioni tramite Eclipse Ventures Fund I, e 1.066.472 azioni tramite Eclipse Continuity Fund I. Le posizioni warrant Series A (5.300.291 azioni sottostanti) e Series B (1.166.935 azioni sottostanti) sono state ridotte a 0.

Owlet (OWLT): Director y propietario del 10% reporta un intercambio warrant-por-acciones. El 10/10/2025, Eclipse Early Growth Fund I, L.P. intercambió warrants emitidos previamente de la Serie A y la Serie B por 3,898,906 acciones ordinarias, a ratios aproximados de 0,61 y 0,56 acciones por warrant, respectivamente. La transacción se reportó como exenta bajo la Regla 16b-3.

Tras el intercambio, la propiedad beneficiaria indirecta reportada incluye 5.665.669 acciones vía Eclipse EGF I, 968.694 acciones vía Eclipse Ventures Fund I, y 1.066.472 acciones vía Eclipse Continuity Fund I. Las posiciones de warrantes de la Serie A (5.300.291 acciones subyacentes) y Serie B (1.166.935 acciones subyacentes) se redujeron a 0.

Owlet (OWLT): 이사 겸 10% 소유주가 워런트-주식 교환을 보고합니다. 2025년 10월 10일, Eclipse Early Growth Fund I, L.P.는 미발행 시리즈 A 및 시리즈 B 워런트를 3,898,906주의 보통주로 교환했으며, 각각 대략 0.610.56 워런트당 주식비율에 해당합니다. 이 거래는 Rule 16b-3에 따라 면책으로 보고되었습니다.

교환 후 간접적 유익 소유는 Eclipse EGF I를 통해 5,665,669주, Eclipse Ventures Fund I를 통해 968,694주, Eclipse Continuity Fund I를 통해 1,066,472주를 포함합니다. 시리즈 A의 기초주 5,300,291주와 시리즈 B의 기초주 1,166,935주는 각각 0으로 감소했습니다.

Owlet (OWLT) : Le directeur et propriétaire de 10% déclare un échange warrant-contre-action. Le 10/10/2025, Eclipse Early Growth Fund I, L.P. a échangé des warrants émis antérieurement des séries A et B contre 3 898 906 actions ordinaires, à des ratios approximatifs de 0,61 et 0,56 actions par warrant, respectivement. La transaction a été déclarée exemptée en vertu de la Rule 16b-3.

Suite à l'échange, la propriété bénéficiaire indirecte reportée comprend 5 665 669 actions via Eclipse EGF I, 968 694 actions via Eclipse Ventures Fund I et 1 066 472 actions via Eclipse Continuity Fund I. Les positions warrants de la série A (5 300 291 actions sous-jacentes) et de la série B (1 166 935 actions sous-jacentes) ont été ramenées à 0.

Owlet (OWLT): Direktor und 10%-Eigentümer meldet warrant-zu-aktie Tausch. Am 10.10.2025 tauschte Eclipse Early Growth Fund I, L.P. zuvor ausgegebene Serien-A- und Serien-B-Warrants gegen 3.898.906 Stammaktien zu ungefährem Verhältnis von 0,61 bzw. 0,56 Aktien pro Warrants, bzw. Die Transaktion wurde gemäß Rule 16b-3 als befreit berichtet.

Nach dem Austausch umfasst die indirekte begünstigte Eigentümerschaft 5.665.669 Aktien über Eclipse EGF I, 968.694 Aktien über Eclipse Ventures Fund I und 1.066.472 Aktien über Eclipse Continuity Fund I. Die Warrants-Positionen der Serie A (5.300.291 zugrundeliegende Aktien) und Serie B (1.166.935 zugrundeliegende Aktien) wurden auf 0 reduziert.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Susan Lior

(Last) (First) (Middle)
C/O OWLET, INC.
3300 NORTH ASHTON BOULEVARD, SUITE 300

(Street)
LEHI UT 84043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Owlet, Inc. [ OWLT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/10/2025 A(1) 3,898,906 A (1) 5,665,669 I See footnote(2)
Common Stock 968,694 I See footnote(3)
Common Stock 1,066,472 I See footnote(4)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series A Warrants (Right to Purchase Shares of Common Stock) (1) 10/10/2025 D(1) 5,300,291 (1) (1) Class A Common Stock 5,300,291 (1) 0 I See footnote(2)
Series B Warrants (Right to Purchase Shares of Common Stock) (1) 10/10/2025 D(1) 1,166,935 (1) (1) Class A Common Stock 1,166,935 (1) 0 I See footnote(2)
Explanation of Responses:
1. On October 10, 2025, Eclipse Early Growth Fund I, L.P. ("Eclipse EGF I") exchanged (a) warrants to purchase shares of Class A common stock, par value $0.0001 per share, of the Company (the "Common Stock"), that were initially issued in February 2023 in connection with the Company's issuance and sale of Series A Convertible Preferred Stock and (b) warrants to purchase shares of Common Stock that were initially issued in February 2024 in connection with the Company's issuance and sale of Series B Convertible Preferred Stock for the shares of Common Stock reported herein at a ratio of approximately 0.61 and 0.56 shares per warrant, respectively. The disposition or deemed disposition of the warrants and any shares of Common Stock that may have been be acquired upon exercise of such warrants and the acquisition of Common Stock in this exchange were exempted from Section 16(b) of the Act pursuant to Rule 16b-3 thereunder.
2. The securities are held of record by Eclipse EGF I. Eclipse Early Growth GP I, LLC ("Eclipse EG GP I") is the general partner of Eclipse EGF I and may be deemed to have voting and dispositive power over the shares held by Eclipse EGF I. The Reporting Person is the sole managing member of Eclipse EG GP I and may be deemed to have voting and dispositive power over the shares held by Eclipse EGF I. Eclipse EG GP I and the Reporting Person disclaim beneficial ownership of the shares held by Eclipse EGF I except to the extent of their respective pecuniary interests therein, if any.
3. The securities are held of record by Eclipse Ventures Fund I, L.P. ("Eclipse I"). Eclipse Ventures GP I, LLC ("Eclipse I GP") is the general partner of Eclipse I and may be deemed to have voting and dispositive power over the shares held by Eclipse I. The Reporting Person, a member of the Issuer's board of directors, is the sole managing member of Eclipse I GP and may be deemed to have voting and dispositive power over the shares held by Eclipse I. Eclipse I GP and the Reporting Person disclaim beneficial ownership of the shares held by Eclipse I except to the extent of their respective pecuniary interests therein, if any.
4. The securities are held of record by Eclipse Continuity Fund I, L.P. ("Eclipse Continuity I"). Eclipse Continuity GP I, LLC ("Eclipse Continuity GP") is the general partner of Eclipse Continuity I and may be deemed to have voting and dispositive power over the shares held by Eclipse Continuity I. The Reporting Person, a member of the Issuer's board of directors, is the sole managing member of Eclipse Continuity GP and may be deemed to have voting and dispositive power over the shares held by Eclipse Continuity I. Eclipse Continuity GP and the Reporting Person disclaim beneficial ownership of the shares held by Eclipse Continuity I except to the extent of their respective pecuniary interests therein, if any.
/s/ Lior Susan 10/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Owlet (OWLT) insider report on the Form 4?

An exchange of Series A and B warrants for 3,898,906 shares of Common Stock on 10/10/2025, exempt under Rule 16b-3.

How many shares does the reporting person indirectly own after the transaction?

Indirect holdings include 5,665,669 shares via Eclipse EGF I, 968,694 via Eclipse Ventures Fund I, and 1,066,472 via Eclipse Continuity Fund I.

What happened to the Owlet warrants referenced in the filing?

Series A warrants tied to 5,300,291 shares and Series B warrants tied to 1,166,935 shares were reduced to 0 following the exchange.

What were the exchange ratios for the warrant-for-share transaction?

Approximately 0.61 shares per Series A warrant and 0.56 shares per Series B warrant.

What is the reporting person’s relationship to Owlet (OWLT)?

The reporting person is a Director and a 10% Owner.

Which entities hold the reported indirect positions?

Eclipse Early Growth Fund I, L.P.; Eclipse Ventures Fund I, L.P.; and Eclipse Continuity Fund I, L.P., with control via affiliated general partners.
Owlet Inc

NYSE:OWLT

OWLT Rankings

OWLT Latest News

OWLT Latest SEC Filings

OWLT Stock Data

152.31M
15.47M
6.76%
54.3%
2.65%
Medical Devices
Measuring & Controlling Devices, Nec
Link
United States
LEHI